603945-44-4

Upstream product

• 100-39-0 benzyl bromide 
• 2011-06-5 2-benzyloxy-3-methoxybenzaldehyde 
• 148-53-8 3-methoxy-2-hydroxybenzaldehyde 

Downstream Products

• 152362-59-9 5-(benzyloxy)-2-(2,2-diphenylacetyl)-6-methoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid ethyl ester 
• 1316755-16-4 5-(benzyloxy)-2-(2,2-diphenylacetyl)-6-methoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid 
• 1316755-16-4 PD 126055 

Relevant academic research and scientific papers

ANGIOTENSIN II RECEPTOR 2 ANTAGONIST SALT FORM AND CRYSTALLINE FORM, AND PREPARATION METHOD THEREFOR

Disclosed are an angiotensin II receptor 2 (AT2R) antagonist salt form and crystalline form, a preparation method therefor, and an application of the salt form and crystalline form in preparing a drug which treats chronic pain.

CARBOXYLIC ACID DERIVATIVE AS AT2R RECEPTOR ANTAGONIST

The present invention relates to a compound shown in formula (II) or a pharmaceutically acceptable salt thereof and an application of the same in preparing a drug for treating a disease related to angiotensin II receptor type 2 (AT2R).(II)

Synthesis of enantiopure angiotensin II type 2 receptor [AT2R] antagonist EMA401

We report a facile synthesis of the angiotensin II type 2 receptor antagonist EMA401, which recently passed phase II clinical trials, in high overall yield. The synthesis of the key phenylalanine intermediate involved the formation of an α-nitro cinnamic ester and its reduction followed by a Pictet-Spengler cyclization, which furnished the tetrahydroisoquinoline core structure. Next, EMA401 was separated from its enantiomer EMA402 by four recrystalizations of a diastereomeric salt in 98% ee. All steps were performed on gram scale with emphasis on avoiding column purification and using readily available low cost starting materials and reagents.